IGC Pharma, Inc.: Form 10-Q for the period ended Dec 31, 2022
Filed with the SEC on Feb 14, 2023 and accepted by EDGAR at Feb 14, 2023, 16:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-10-01 to 2022-12-31 | $332.0k | us-gaap:Revenues |
| Revenue | 9 months2022-04-01 to 2022-12-31 | $745.0k | us-gaap:Revenues |
| Cost of revenue | 3 months2022-10-01 to 2022-12-31 | $230.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2022-04-01 to 2022-12-31 | $366.0k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-10-01 to 2022-12-31 | $102.0k | us-gaap:GrossProfit |
| Gross profit | 9 months2022-04-01 to 2022-12-31 | $379.0k | us-gaap:GrossProfit |
| Research and development | 3 months2022-10-01 to 2022-12-31 | $806.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-04-01 to 2022-12-31 | $3.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-10-01 to 2022-12-31 | $1.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-04-01 to 2022-12-31 | $4.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-10-01 to 2022-12-31 | −$2.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-04-01 to 2022-12-31 | −$7.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-10-01 to 2022-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-04-01 to 2022-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-10-01 to 2022-12-31 | −$2.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-04-01 to 2022-12-31 | −$7.5m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2022-04-01 to 2022-12-31 | −$5.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-12-31 | $4.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $9.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $20.1m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $1.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $1.8m | us-gaap:Liabilities |
| Long-term debt | At period end2022-12-31 | $141.0k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2022-12-31 | $3.0k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2022-12-31 | $18.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001185185-23-000133. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.